PT-141 (Bremelanotide)
Explore PT-141 and bremelanotide, including melanocortin-receptor biology, FDA-approved use, clinical evidence, safety considerations, and prescription pathways.
What Is PT-141 (Bremelanotide)?
Bremelanotide, commonly called PT-141, is a synthetic melanocortin-receptor agonist. Unlike medicines that act primarily through peripheral blood flow, bremelanotide acts through central melanocortin pathways involved in sexual response.
An FDA-approved bremelanotide product is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD, when low desire causes marked distress and is not due to a medical or psychiatric condition, relationship problem, or effects of medication or another substance.
It is not indicated for men, postmenopausal women, enhancement of sexual performance, or treatment of other sexual dysfunctions. Treatment requires a prescription and product-specific screening, dosing, and counseling.
What Has Bremelanotide Been Studied For?
Randomized clinical trials evaluated on-demand bremelanotide in premenopausal women with acquired, generalized HSDD. The approved indication reflects that defined population and diagnostic criteria.
Research has also explored melanocortin signaling and other sexual-function populations, but those investigations do not establish approved use in men, postmenopausal women, or people whose symptoms have another underlying cause.
Diagnosis should include evaluation of medical, medication-related, psychological, and relationship factors before treatment is considered.
Bremelanotide: Approved Use & Compounding Status
Bremelanotide is available in an FDA-approved prescription product for a specific population and indication. The approved product's formulation, dose, instructions, and safety information should guide treatment.
A compounded bremelanotide preparation is not FDA-approved and should not be described as generic or identical to the approved product. Compounding may be considered only when current requirements are satisfied and a licensed prescriber identifies a patient-specific medical need that cannot be met by the approved product.
Freedom's pharmacists can help distinguish the approved pathway from any individualized formulation question and verify current availability.
Bremelanotide Prescription Pathways
-
FDA-Approved Bremelanotide
Explore Bremelanotide OptionsFDA-approved bremelanotide has a specific indication, single-dose autoinjector formulation, dosing limits, administration instructions, and safety information. Treatment should follow the approved labeling.
-
Patient-Specific Questions
Talk to a PharmacistFreedom's pharmacists can help patients and licensed prescribers distinguish the approved product pathway from any individualized formulation question and verify current options.
PT-141 (Bremelanotide) Frequently Asked Questions
Is bremelanotide FDA approved?
Yes. FDA has approved a bremelanotide product for premenopausal women with acquired, generalized HSDD who meet the labeled criteria. Compounded bremelanotide is not FDA-approved.
Can Freedom compound bremelanotide?
Freedom can review current patient-specific questions with licensed prescribers. Any compounded preparation would not be FDA-approved and may be considered only when current requirements are satisfied and the approved product cannot meet an identified patient's medical need.
Does bremelanotide require a prescription?
Yes. Bremelanotide is a prescription medication and requires evaluation by a licensed healthcare professional.
How does bremelanotide work?
Bremelanotide activates melanocortin receptors in central pathways involved in sexual response. Its mechanism differs from medicines that act primarily through peripheral blood flow.
Who is FDA-approved bremelanotide intended for?
The approved indication is limited to premenopausal women with acquired, generalized HSDD that causes marked distress and is not explained by another condition, relationship problem, medication, or substance.
What are important bremelanotide safety considerations?
No. Commercially manufactured consumer products are distinct from patient-specific compounded prescriThe approved product is contraindicated in uncontrolled hypertension or known cardiovascular disease. Labeling also addresses transient blood-pressure increases, heart-rate reductions, nausea, focal hyperpigmentation, and effects on absorption of oral medicines.tion medications.
Does Freedom sell research-use-only PT-141?
No. Freedom Compounding Pharmacy serves patients and licensed healthcare providers and does not sell research-use-only peptides.
Questions About PT-141 or Bremelanotide?
Freedom Compounding Pharmacy can help patients and licensed healthcare providers understand bremelanotide's approved use, safety considerations, and current prescription pathways.